<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To identify risk factors associated with the development of <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and to describe the prevalence of <z:mp ids='MP_0002055'>diabetes</z:mp> in pediatric hematopoietic cell transplant (HCT) survivors </plain></SENT>
<SENT sid="1" pm="."><plain>The follow-up records of 748 patients who survived for at least 2 years after pediatric HCT were retrospectively reviewed for diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Risk factors for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were analyzed using multivariate statistics </plain></SENT>
<SENT sid="3" pm="."><plain>Among 748 patients with a median of 11 years of follow-up, 38 developed <z:mp ids='MP_0002055'>diabetes</z:mp> after HCT </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients (three <z:hpo ids='HP_0001909'>leukemia</z:hpo> and one <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo>) developed type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> 8 to 14 years after HCT, at between 10 and 19 years of age </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-four patients (32 <z:hpo ids='HP_0001909'>leukemia</z:hpo> and 2 <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>) developed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> 1 to 24 years after HCT, at between 11 and 41 years of age </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 34 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 23 were non-Hispanic white, 3 had experienced asparaginase toxicity (<z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and/or <z:hpo ids='HP_0001733'>pancreatitis</z:hpo>), and 26 had a family history of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Risk factors associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were diagnosis of <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0005558'>chronic leukemia</z:hpo>, race/ethnicity other than non-Hispanic white, family history of <z:mp ids='MP_0002055'>diabetes</z:mp>, and asparaginase toxicity </plain></SENT>
<SENT sid="8" pm="."><plain>The prevalence of type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> among <z:hpo ids='HP_0000001'>all</z:hpo> surviving patients was 0.52%, or three times higher than the general U.S. population </plain></SENT>
<SENT sid="9" pm="."><plain>The prevalence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was 9% among <z:hpo ids='HP_0001909'>leukemia</z:hpo> survivors and 2% among <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> survivors, both higher than expected </plain></SENT>
<SENT sid="10" pm="."><plain>Pediatric HCT survivors are more likely to develop <z:mp ids='MP_0002055'>diabetes</z:mp> than the general population </plain></SENT>
</text></document>